Paul Schmitt Email & Phone Number

Bethlehem Pa

New Street Ventures has invested in MuReva,SurgeonCheck LLC,Cernostics and Bellrock Intelligence. Mr Schmitt is an active advisor to these companies and serves on the Board of Directors at Bellrock Intelligence and MuReva and as an Advisor to SurgeonCheck.www.surgeoncheck.com www.bellrockintel.com www.cernostics.comNew Street Ventures also provides advisory services to healthcare systems and entrepreneurs seeking acquisitions and strategic partners.

Bethlehem Pa

Responsible for directing all Life Science investments:-Led investments of $32 Million into 9 Fund III (2003- 2017)Life Science startups which attracted over $400Million in follow on capital.-Co-led formation of Tetralogic Pharmaceuticals out of Princeton Univ in 2003. Birinipant considered best in class for inhibition of SMAC Mimetics to treat infectious diseases,hematologic malignancies and solid tumors. IPO on 11/22/13 and follow on financing totaled $106 Million. Served on Board of Directors and as Chairman of the Audit Committee 2003-2015.-Led B Round financing in Renal Soloutions in 2004. Recruited Renal Industry luminary,Don Joseph to Board of Directors. Company sold to Fresenius Medical for $250Million in 2007.-Founding investor in Amorcyte and CEO, 2010-2012. In conjunction with Scientific/Clinical Founder launched Phase II randomized, double blind clinical trial in severe AMI,established dominant IP position for use of autologous CD34+/CXCR4+ cells in cardiovascular disease,quantified reimbursement strategy and completed merger with Neostem (NASDAQ:NBS).

Bethlehem, Pennsylvania

Allendale Nj

Representing Novitas, Mr. Schmitt was a founding investor and CEO of Amorcyte, a cardiovascular stem cell therapy company founded out of Hackensack University Medical Center and Progenitor Cell Therapy Inc. As CEO, Mr. Schmitt and the Scientific /Clinical founder, Dr. Andrew Pecora, launched a phase II randomized, double blind clinical study in severe AMI patients, established a dominant IP position for use of autologous CD34+/CXCR4+ cells in cardiovascular disease, quantified a reimbursement strategy and completed a merger with Neostem (NASDAQ:NBS).

Chief Executive Officer for Global CRO (NASDAQ:CRLS)providing transgenic, pre-clinical and clinical services to over 250 pharmaceutical and biotech clients in 23 countries.

Princeton Nj

Parallel to building Chrysalis, formed Nextran, a JV with Baxter Health Care and served as President and Board Member until its sale to Baxter in 1995. Nextran focused on utilizing DNX Corp. technology for genetically engineered swine as a source of blood substitutes and organs suitable for human transplant. Nextran completed the first successful ex-vivo transplants of genetically engineered pig livers to humans at Duke University in 1995.

Princeton Nj

Recruited to DNX Corp. to lead a venture funded startup in development and commercialization of transgenic animal technologies licensed from Founders/Academic Partners at Princeton University and Ohio University. DNX completed a B Round financing and IPO in 1991 raising $56MM largely based on successes in genetically engineering swine as a source of human blood substitutes and organs for transplant into humans.DNX was also a leader in utilizing transgenic technologies as a pre-clinical service business to identify and validate new human genetic targets of disease emerging from worldwide genomic initiatives.The transgenic services business provided a platform to aquire and grow additional pre-clinical and Phase I II III clinical companies into a Global CRO with over 250 Biotech/Pharmaceutical industry clients in 23 countries and operating companies in Lyon(FR),Dusseldorf (HR), Zug(Switz.) , Haifa (IL), Czech Republic, Austin Texas and Scranton Pa.This business was renamed Chrysalis International in 1996 and sold to Phoenix International in 1999.DNX's organ transplant and blood substitute technologies were merged into a Joint Venture,Nextran with Baxter Health Care in 1994. Nextran successfully completed the first ex-vivo transplants of genetically engineered pig livers to humans at Duke University in 1995 and was acquired by Baxter shortly thereafter.

Hackensack Nj

Mr, Schmitt was recruited to this fully integrated orthopedic company to lead commercialization of Orthopak,an electronic bone growth stimulator for long bone fractures which had a distribution agreement with Bristol Myers/Zimmer. In addition ,he conceived and launched a clinical program for high risk fresh fractures.

Orchard Park, Ny

As Chief Executive and General Manager, Mr Schmitt was responsible for leading the transformation of a low growth,unprofitable medical anesthesia and respiratory therapy business into two high growth emergency medical and dental airway management businesses. Transformational Emergency Medical and Trauma products were developed in collaboration with Dr. Ron Stewart,Director of EMS for the University of Pittsburgh Medical Center/City of Pittsburgh.

Montvale Nj

Montvale Nj

World Headquarters, East Hanover Nj

1974-75 Financial Management Training program1975-76 Financial Analyst-Planning and Budgets1976-77 Financial Analyst-Capital Expenditures1977-78 Assistant Controller- Food Services Division

Bs, Finance

Activities and Societies: Varsity Lacrosse Varsity Football Vice President Delta Tau Delta

Mba

Activities and Societies: Board of Managers 1997-2002